Retatrutide FAQ: 15 Questions Researchers Ask Before Buying

For laboratory and research use only. Not for human consumption.

Retatrutide (LY3437943) has generated more research interest per year than almost any other investigational peptide. Phase 2 trials showed 24% body weight reduction at 48 weeks. Phase 2a MASLD data showed 82–86% liver fat reduction. Phase 3 trials are ongoing.

Researchers who want to work with it have a lot of questions. Here are the 15 we hear most often — answered with reference to the published data.

Q1: What Exactly Is Retatrutide?

Retatrutide is a 39-amino-acid synthetic peptide developed by Eli Lilly. Its research designation is LY3437943. It’s the first investigational compound to simultaneously activate three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor).

That “triple agonist” classification is what distinguishes it from everything that came before. Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GLP-1 + GIP). Retatrutide adds glucagon receptor activation on top of both.

It’s not approved by the FDA or any regulatory authority. It’s an investigational compound in Phase 3 trials. It’s available as a research peptide for laboratory use only.

Q2: How Does the Triple Agonist Mechanism Work?

Each receptor pathway contributes differently:

GLP-1 receptor — Triggers satiety signaling in the hypothalamus, slows gastric emptying, and stimulates glucose-dependent insulin secretion. This is the same pathway semaglutide acts on.

GIP receptor — Potentiates insulin release (it’s actually the dominant incretin hormone, responsible for a large fraction of the postprandial insulin response). Also involved in lipid metabolism in adipose tissue and potentially beta-cell survival.

Glucagon receptor (GCGR) — This is the differentiator. GCGR activation in the liver promotes fatty acid oxidation and reduces hepatic lipid accumulation. It also increases resting energy expenditure — potentially through activation of brown adipose tissue. This mechanism is why retatrutide shows such pronounced effects on liver fat in MASLD research.

In vitro receptor binding studies found retatrutide’s potency hierarchy: GIP receptor (EC50: 0.0643 nM) > GLP-1 receptor (EC50: 0.775 nM) > Glucagon receptor (EC50: 5.79 nM). The concurrent GLP-1 and GIP activation appears to counterbalance the glucose-raising effects of glucagon receptor activation (NEJM, 2023).

Q3: What Clinical Data Exists?

More than for almost any other investigational peptide. Here’s the published record as of early 2026:

Phase 2 obesity trial (NEJM, 2023) — 338 adults with obesity/overweight, 48 weeks, randomized double-blind. At the highest dose (12mg), mean body weight reduction was 24.2% vs. 2.1% placebo. About 26% of subjects at the top dose achieved ≥30% body weight reduction — a threshold rarely seen with pharmacological interventions (Jastreboff et al., NEJM 2023).

Phase 2 type 2 diabetes trial (Lancet, 2023) — Significant HbA1c reductions alongside body weight changes (Rosenstock et al., Lancet 2023).

Phase 2a MASLD trial (Nature Medicine, 2024) — 82–86% relative reduction in liver fat by MRI-PDFF. Over 85% of subjects achieved steatosis resolution (liver fat below 5%) (Sanyal et al., Nature Medicine 2024).

Phase 3 TRIUMPH-4 (December 2025) — Body weight reduction of 26.4–28.7% at highest dose, plus co-primary endpoint of knee pain reduction in osteoarthritis met (Lilly IR, December 2025).

TRIUMPH-1 (obesity), TRIUMPH-2 (type 2 diabetes), TRIUMPH-3 (weight maintenance), and additional trials in cardiovascular outcomes, sleep apnea, and MASLD are ongoing.

Q4: How Do You Reconstitute Retatrutide?

Standard peptide reconstitution procedure applies:

1. Wipe both vials (peptide and bacteriostatic water) with an alcohol swab
2. Draw the desired volume of bacteriostatic water into an insulin syringe
3. Inject the BAC water slowly down the inside wall of the peptide vial — not directly onto the powder cake
4. Swirl gently until fully dissolved. Never shake
5. The solution should be clear. Cloudiness indicates degradation

Use bacteriostatic water (0.9% benzyl alcohol), not plain sterile water. The preservative extends the shelf life of your reconstituted solution from single-use to approximately 20–30 days when refrigerated.

Reconstitution Concentration Reference

Q5: What Dosing Did Clinical Trials Use?

Published Phase 2 trials used once-weekly subcutaneous injections with gradual dose escalation:

• Starting doses: 1mg/week, escalating over several weeks
• Dose cohorts studied: 1mg, 4mg, 8mg, 12mg
• Peak dose showing greatest efficacy: 12mg/week
• Administration: subcutaneous injection, once weekly
• Study duration: 48 weeks

The dose escalation protocol is important. Starting at full dose produces more gastrointestinal side effects. The published trials used a gradual titration approach — starting low, increasing over several weeks — which reduced the incidence and severity of nausea and other GI effects.

These are clinical trial parameters for human subjects in controlled settings. They’re not validated protocols for other research contexts.

Q6: How Do You Store Retatrutide?

Key rules: protect from light (UV degrades peptides), never shake, never freeze a reconstituted solution (freeze-thaw cycles damage the peptide structure), and use bacteriostatic water — not plain water — for multi-day protocols.

Q7: How Long Until Research Endpoints Are Observable?

Based on published clinical trial data:

• Weeks 4–8: Early weight reduction visible in Phase 2 dose cohorts
• Week 12: Meaningful body weight reduction becoming apparent across dose groups
• Week 24: Substantial effects in higher-dose cohorts (12–18% body weight reduction in Phase 2)
• Week 48: Peak outcomes measured in the published Phase 2 trial (24.2% at 12mg)
• Liver fat (MASLD): 82–86% reduction measured at 48 weeks

There was no plateau observed at 48 weeks in the Phase 2 high-dose cohort — suggesting longer studies might show continued effects.

Q8: What Side Effects Were Observed in Trials?

The Phase 2 safety profile was characterized as generally consistent with incretin-class peptides (PMC12190491):

Most common adverse events:

• Nausea — most frequent, dose-dependent, most pronounced during dose escalation
• Diarrhea — mild to moderate in most cases
• Decreased appetite — consistent across dose groups
• Vomiting and constipation — less frequent

Discontinuation due to adverse events was approximately 6% across active treatment groups in Phase 2 — relatively low.

Areas requiring further investigation:

• Long-term safety beyond 48 weeks (Phase 3 trials will address this)
• Glucagon receptor-specific effects on glucose homeostasis over extended periods
• Gallbladder events (monitored across the class)
• Safety in renally impaired, hepatically impaired, elderly, and adolescent populations

All safety data comes from controlled clinical trial settings with specific inclusion/exclusion criteria. Phase 3 will expand the data set significantly.

Q9: Can You Stack Retatrutide With Other Peptides?

There is no published clinical data on co-administration of retatrutide with other research peptides. The Phase 2 and Phase 3 trials are single-agent studies.

Combination protocols would require careful consideration of mechanism overlap and potential additive effects. For example: combining retatrutide (which already activates GLP-1 receptors) with another GLP-1 agonist like semaglutide would represent redundant pathway activation with no demonstrated benefit and potential for compounded side effects.

Stacking decisions in research should be grounded in mechanism understanding, not assumed synergy. The published research base for retatrutide combinations is essentially zero as of early 2026.

Q10: How Does Retatrutide Compare to Semaglutide and Tirzepatide?

Cross-trial comparisons have inherent limitations — different populations, protocols, and study durations. Head-to-head trials have not been published. But the apparent progression from single to dual to triple agonism correlates with increasing efficacy in published data (PMC12026077).

NorthPeptide carries semaglutide and tirzepatide as research peptides alongside retatrutide.

Q11: Is Retatrutide FDA-Approved?

No. As of early 2026, retatrutide is an investigational compound with no regulatory approval from the FDA or any other authority. It’s in Phase 3 clinical trials under Eli Lilly’s TRIUMPH program. Regulatory submission is anticipated in late 2026 to mid-2027, contingent on Phase 3 results.

It is not available through licensed pharmacies or prescription. It is available as a research peptide for laboratory and research use only.

Q12: What Purity Standards Should You Expect?

Research-grade peptides should meet a minimum of ≥98% purity by HPLC (high-performance liquid chromatography). This is the standard used in published laboratory research.

Third-party testing is the critical verification step. The supplier’s own testing is not independent — it’s a conflict of interest. What you want is a Certificate of Analysis (CoA) from a qualified external laboratory. Janoshik Analytical (Czech Republic) has become the industry standard for independent peptide verification, using both HPLC and mass spectrometry to confirm identity and purity.

What to look for in a CoA:

• HPLC purity ≥98%
• Mass spectrometry confirmation of correct molecular mass (~4,562 Da for retatrutide)
• Laboratory name and date that matches the batch
• A verifiable document (not just a screenshot)

Any supplier who doesn’t provide a third-party CoA for every batch is a quality red flag. Impure peptide confounds research results and introduces unknown variables.

Q13: What About Shipping and Customs?

Research peptides ship internationally as research chemicals. Customs regulations vary significantly by country, and the regulatory landscape continues to evolve. In most jurisdictions, research peptides are not controlled substances and can be imported for legitimate research purposes.

Key considerations:

• Peptides are not controlled substances in most countries
• Lyophilized peptides at room temperature are stable for shipping and don’t require cold chain
• Retatrutide is not on most customs watch lists as it’s an investigational compound, not a scheduled substance
• Always verify the import regulations for your specific country before ordering

NorthPeptide ships internationally and offers a customs guarantee — free reship if a package is seized at customs.

Q14: Who Should Be Researching Retatrutide?

Based on the published data, the most relevant research contexts are:

• Metabolic research — obesity, body composition, energy expenditure, adipose tissue biology
• Hepatology research — MASLD, hepatic steatosis, liver fat metabolism
• Endocrinology — incretin biology, pancreatic beta-cell function, glycemic regulation
• Comparative pharmacology — comparison of GLP-1, dual agonist, and triple agonist mechanisms
• Cardiovascular research — metabolic-cardiovascular interactions (ongoing TRIUMPH CVOT)

Retatrutide is not appropriate for research contexts where the target is tissue repair, neuroprotection, or non-metabolic applications. The published evidence base is essentially all metabolic and hepatic.

Q15: Where Can You Buy Quality Retatrutide for Research?

Quality indicators to evaluate:

1. Third-party CoA from Janoshik or equivalent — per batch, not generic. HPLC + mass spec, not just one method
2. Purity ≥98% by HPLC — the research-grade standard
3. Correct molecular mass confirmed — mass spec should show ~4,562 Da
4. Lyophilized form — more stable than pre-reconstituted liquid
5. Clear labeling — research use only, not for human consumption
6. Transparent supplier — publishes CoAs, has verifiable contact information, doesn’t make therapeutic claims

NorthPeptide carries research-grade retatrutide with Janoshik CoA, ≥98% purity by HPLC, and international shipping.

Summary of Key Research References